{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:12:01Z","timestamp":1767823921421,"version":"3.49.0"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2009,8,14]],"date-time":"2009-08-14T00:00:00Z","timestamp":1250208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Dexlansoprazole MR, a modified\u2010release formulation of dexlansoprazole, an enantiomer of lansoprazole, effectively heals erosive oesophagitis.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To assess dexlansoprazole MR in maintaining healed erosive oesophagitis.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Patients (<jats:italic>n<\/jats:italic>\u2003=\u2003451) with erosive oesophagitis healed in either of two dexlansoprazole MR healing trials randomly received dexlansoprazole MR 60 or 90\u2003mg or placebo once daily in this double\u2010blind trial. The percentage of patients who maintained healing at month 6 was analysed using life table and crude rate methods. Secondary endpoints were percentages of nights and of 24\u2010h days without heartburn based on daily diaries.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Dexlansoprazole MR 60 and 90\u2003mg were superior to placebo for maintaining healing (<jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.0025). Maintenance rates were 87% and 82% for the 60 and 90\u2003mg doses, respectively, vs. 26% for placebo (life table), and 66% and 65% vs. 14%, respectively (crude rate). Both doses were superior to placebo for the percentage of 24\u2010h heartburn\u2010free days (60\u2003mg, 96%; 90\u2003mg, 94%; placebo, 19%) and nights (98%, 97%, and 50%, respectively). Diarrhoea, flatulence, gastritis (symptoms) and abdominal pain occurred more frequently with dexlansoprazole MR than placebo, but were not dose\u2010related.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Dexlansoprazole MR effectively maintained healed erosive oesophagitis and symptom relief compared with placebo, and was well tolerated.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2009.04119.x","type":"journal-article","created":{"date-parts":[[2009,8,14]],"date-time":"2009-08-14T19:25:57Z","timestamp":1250277957000},"page":"895-907","source":"Crossref","is-referenced-by-count":36,"title":["Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90\u2003mg in healed erosive oesophagitis \u2013 maintenance of healing and symptom relief"],"prefix":"10.1111","volume":"30","author":[{"given":"C. W.","family":"HOWDEN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"LARSEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"PEREZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"PALMER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. N.","family":"ATKINSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,10,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61790-X"},{"key":"e_1_2_6_3_2","first-page":"326","article-title":"Gastroesophageal reflux disease","volume":"12","author":"Rai A","year":"1998","journal-title":"Curr Opin Gastroenterol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1155\/1998\/925346","article-title":"The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts","volume":"12","author":"Thomson AB","year":"1998","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_6_5_2","first-page":"90","article-title":"Medical treatment of gastroesophageal reflux disease in the managed care environment","volume":"8","author":"Fennerty MB","year":"1997","journal-title":"Semin Gastrointest Dis"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41217.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2001.09.1017"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199802000-00004"},{"key":"e_1_2_6_9_2","first-page":"66B","article-title":"Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview","volume":"11","author":"Chiba N","year":"1997","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.44.2008.S1"},{"key":"e_1_2_6_11_2","first-page":"1","article-title":"Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease","volume":"4","author":"Donnellan C","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.03.006"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02643.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01464.x"},{"issue":"4","key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"A176","DOI":"10.1016\/S0016-5085(08)60818-5","article-title":"The pharmacokinetics of TAK\u2010390MR 60\u2003mg, a dual delayed release formulation of the proton pump inhibitor TAK\u2010390, and lansoprazole 60\u2003mg: a retrospective analysis [abstract S1095]","volume":"134","author":"Mayer MD","year":"2008","journal-title":"Gastroenterology"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802693883"},{"issue":"52","key":"e_1_2_6_17_2","first-page":"A487","article-title":"Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60\u2003mg, 90\u2003mg, and 120\u2003mg oral doses of modified\u2010release TAK\u2010390 (TAK\u2010390MR) and 30\u2003mg oral doses of lansoprazole in healthy subjects","volume":"132","author":"Zhang W","year":"2007","journal-title":"Gastroenterology"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.03933.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03443.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01024.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200323020-00001"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05769.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01745.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00349-0"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-8751-3"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-9567-x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/75.4.800"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00008"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200107000-00008"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.03954.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2009.04119.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2009.04119.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T18:57:52Z","timestamp":1697223472000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2009.04119.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,6]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1365-2036.2009.04119.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04119.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,6]]}}}